首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
【24h】

Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data

机译:大量慢性和症状性心力衰竭患者中B型利钠肽(BNP)和氨基末端proBNP的直接比较:缬沙坦心力衰竭(Val-HeFT)数据

获取原文
           

摘要

Background: The B-type or brain natriuretic peptides (BNP) and the amino-terminal probrain natriuretic peptide (NT-proBNP) are good markers of prognosis and diagnosis in chronic heart failure (HF). It is unclear, however, whether differences in their biological characteristics modify their clinical correlates and prognostic performance in HF. This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF.Methods: We measured BNP and NT-proBNP at baseline in 3916 patients enrolled in the Valsartan Heart Failure Trial. To identify the variables associated with both peptides, we conducted simple and multivariable linear regression analyses. We used Cox multivariable regression models to evaluate the independent prognostic value for all-cause mortality, mortality and morbidity, and hospitalization for HF. Prognostic performance was assessed by pairwise comparisons of the area under the curve of receiver-operator characteristic curves.Results: NT-proBNP and BNP had similar relationships with age, left ventrical ejection fraction, and internal diameter and creatinine clearance. Either peptide ranked as the first independent predictor of outcome after adjustment for major confounding clinical characteristics. ROC curves were almost superimposable for all-cause mortality (area under the curve (SE): BNP 0.665 (0.011) vs NT-proBNP 0.679 (0.011); P = 0.0734), but NT-proBNP was superior to BNP for predicting mortality and morbidity ( P = 0.032) or hospitalization for HF ( P = 0.0143). Overall sensitivity and specificity ranged from 0.590 to 0.696.Conclusions: The natriuretic peptides BNP and NT-proBNP showed subtle differences in their relation to clinical characteristics and prognostic performance in a large population of patients with chronic and stable HF. They were the most powerful independent markers of outcome in HF.
机译:背景:B型或脑利钠肽(BNP)和氨基末端脑钠肽(NT-proBNP)是慢性心力衰竭(HF)预后和诊断的良好标志。然而,尚不清楚它们的生物学特性差异是否会改变其临床相关性和HF的预后性能。这项工作旨在直接比较慢性和稳定HF患者的BNP和NT-proBNP的预后价值。方法:我们在参加Valsartan心力衰竭试验的3916例患者的基线时测量了BNP和NT-proBNP。为了鉴定与两种肽相关的变量,我们进行了简单和多变量线性回归分析。我们使用Cox多变量回归模型评估全因死亡率,死亡率和发病率以及HF住院的独立预后价值。结果:NT-proBNP和BNP与年龄,左心室射血分数,内径和肌酐清除率有相似的关系。在对主要混杂临床特征进行调整后,这两种肽均被视为结果的第一个独立预测因子。 ROC曲线几乎可以覆盖所有原因的死亡率(曲线下的面积(SE):BNP 0.665(0.011)vs NT-proBNP 0.679(0.011); P = 0.0734),但是NT-proBNP在预测死亡率和死亡率方面优于BNP。发病率(P = 0.032)或因心力衰竭住院(P = 0.0143)。总体敏感性和特异性在0.590至0.696之间。结论:利钠肽BNP和NT-proBNP在与大量慢性和稳定的HF患者的临床特征和预后表现之间存在细微的差异。它们是心力衰竭结果中最有力的独立指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号